Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Iovance Biotherapeutics Inc IOVA

Healthcare Biotechnology
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.


NDAQ:IOVA - Post by User

Iovance Biotherapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(240)
•••
Post by whytestockson Feb 21, 2024 12:00pm
53 Views
Post# 35891067

Iovance Biotherapeutics Hits New 52-Week High

Iovance Biotherapeutics Hits New 52-Week High
JUST IN: $IOVA Iovance Biotherapeutics Hits New 52-Week High2024-02-21 11:42:05 ET DENVER, Colo., Feb 21, 2024 (www.247marketnews.com)- Iovance Biotherapeutics (NASDAQ: IOVA ) continues to press forward on the strength of the U.S. Food and Drug Administration (FDA) approving its AMTAGVI&#xA0;(lifileucel) suspension for intravenous infusion, on F...IOVA - Iovance Biotherapeutics Hits New 52-Week High

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities